MiraLAX Targeted In Petition To FDA, But Physicians Back Pediatric Use
This article was originally published in The Tan Sheet
Executive Summary
A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.